FI3897646T3 - Masitentaani keuhkovaltimoverenpainetaudin hoitoon - Google Patents
Masitentaani keuhkovaltimoverenpainetaudin hoitoon Download PDFInfo
- Publication number
- FI3897646T3 FI3897646T3 FIEP19832954.2T FI19832954T FI3897646T3 FI 3897646 T3 FI3897646 T3 FI 3897646T3 FI 19832954 T FI19832954 T FI 19832954T FI 3897646 T3 FI3897646 T3 FI 3897646T3
- Authority
- FI
- Finland
- Prior art keywords
- masitentan
- treatment
- prevention
- per day
- pah
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title claims 28
- 229960001039 macitentan Drugs 0.000 title claims 6
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 title claims 6
- 230000002265 prevention Effects 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 claims 4
- 229960003841 selexipag Drugs 0.000 claims 4
- 229960000835 tadalafil Drugs 0.000 claims 4
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 4
- NPDKXVKJRHPDQT-IYARVYRRSA-N chembl3301604 Chemical compound C1C[C@@H](COCC(=O)O)CC[C@@H]1COC(=O)N(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 NPDKXVKJRHPDQT-IYARVYRRSA-N 0.000 claims 3
- 229950005114 ralinepag Drugs 0.000 claims 3
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 2
- 102100026476 Prostacyclin receptor Human genes 0.000 claims 2
- 108091006335 Prostaglandin I receptors Proteins 0.000 claims 2
- 229960002414 ambrisentan Drugs 0.000 claims 2
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims 2
- 229960003065 bosentan Drugs 0.000 claims 2
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims 2
- 239000008109 sodium starch glycolate Substances 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 2
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 1
- 229960002890 beraprost Drugs 0.000 claims 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229960002240 iloprost Drugs 0.000 claims 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 150000003815 prostacyclins Chemical class 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 229960000529 riociguat Drugs 0.000 claims 1
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical group N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229960005032 treprostinil Drugs 0.000 claims 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims 1
- 229960000438 udenafil Drugs 0.000 claims 1
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims 1
- 229960002381 vardenafil Drugs 0.000 claims 1
- QZFHIXARHDBPBY-UHFFFAOYSA-N vericiguat Chemical compound N1=C(N)C(NC(=O)OC)=C(N)N=C1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F QZFHIXARHDBPBY-UHFFFAOYSA-N 0.000 claims 1
- 229950005018 vericiguat Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2018086724 | 2018-12-21 | ||
EP2019051830 | 2019-01-25 | ||
EP2019060151 | 2019-04-18 | ||
EP2019066494 | 2019-06-21 | ||
EP2019067186 | 2019-06-27 | ||
PCT/EP2019/086754 WO2020128017A1 (fr) | 2018-12-21 | 2019-12-20 | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire |
Publications (1)
Publication Number | Publication Date |
---|---|
FI3897646T3 true FI3897646T3 (fi) | 2024-06-26 |
Family
ID=69147670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FIEP19832954.2T FI3897646T3 (fi) | 2018-12-21 | 2019-12-20 | Masitentaani keuhkovaltimoverenpainetaudin hoitoon |
Country Status (19)
Country | Link |
---|---|
US (3) | US11234980B2 (fr) |
EP (1) | EP3897646B1 (fr) |
JP (1) | JP2022512493A (fr) |
KR (1) | KR20210109558A (fr) |
CN (1) | CN113194953A (fr) |
AU (1) | AU2019410727A1 (fr) |
BR (1) | BR112021011999A2 (fr) |
CA (1) | CA3123990A1 (fr) |
CL (1) | CL2021001636A1 (fr) |
CO (1) | CO2021007186A2 (fr) |
FI (1) | FI3897646T3 (fr) |
IL (1) | IL284136A (fr) |
JO (1) | JOP20210153A1 (fr) |
MA (1) | MA54522A (fr) |
MX (1) | MX2021007455A (fr) |
PH (1) | PH12021551371A1 (fr) |
SG (1) | SG11202105098VA (fr) |
WO (1) | WO2020128017A1 (fr) |
ZA (1) | ZA202105111B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230074610A (ko) * | 2017-02-27 | 2023-05-30 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물 |
WO2020128017A1 (fr) | 2018-12-21 | 2020-06-25 | Actelion Pharmaceuticals Ltd | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire |
TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0116237B8 (pt) | 2000-12-18 | 2021-05-25 | Actelion Pharmaceuticals Ltd | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". |
RU2424805C2 (ru) * | 2005-09-12 | 2011-07-27 | Актелион Фармасьютиклз Лтд | Стабильные фармацевтические композиции, включающие пиримидинсульфамид |
AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
MY178894A (en) | 2008-08-13 | 2020-10-21 | Actelion Pharmaceuticals Ltd | Therapeutic compositions containing macitentan |
CA3043283A1 (fr) * | 2016-11-10 | 2018-05-17 | Arena Pharmaceuticals, Inc. | Methodes de traitement de l'htap a l'aide de combinaisons de ralinepag et d'autres agents |
WO2018153925A1 (fr) * | 2017-02-22 | 2018-08-30 | Amneal Pharmaceuticals Company Gmbh | Compositions pharmaceutiques stables comprenant du macitentan |
KR20230074610A (ko) | 2017-02-27 | 2023-05-30 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물 |
WO2020128017A1 (fr) | 2018-12-21 | 2020-06-25 | Actelion Pharmaceuticals Ltd | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire |
TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
TW202103703A (zh) | 2019-04-05 | 2021-02-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療門脈肺高血壓之方法 |
JOP20220126A1 (ar) | 2019-11-26 | 2023-01-30 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية لعلاج أمراض الأوعية الدموية الرئوية و/أو خلل وظيفي في القلب لمرضى فونتان المُخفّف |
-
2019
- 2019-12-20 WO PCT/EP2019/086754 patent/WO2020128017A1/fr unknown
- 2019-12-20 JO JOP/2021/0153A patent/JOP20210153A1/ar unknown
- 2019-12-20 SG SG11202105098VA patent/SG11202105098VA/en unknown
- 2019-12-20 CN CN201980084868.5A patent/CN113194953A/zh active Pending
- 2019-12-20 EP EP19832954.2A patent/EP3897646B1/fr active Active
- 2019-12-20 MX MX2021007455A patent/MX2021007455A/es unknown
- 2019-12-20 MA MA054522A patent/MA54522A/fr unknown
- 2019-12-20 BR BR112021011999-0A patent/BR112021011999A2/pt unknown
- 2019-12-20 JP JP2021533836A patent/JP2022512493A/ja active Pending
- 2019-12-20 KR KR1020217022508A patent/KR20210109558A/ko unknown
- 2019-12-20 FI FIEP19832954.2T patent/FI3897646T3/fi active
- 2019-12-20 AU AU2019410727A patent/AU2019410727A1/en active Pending
- 2019-12-20 CA CA3123990A patent/CA3123990A1/fr active Pending
-
2021
- 2021-03-02 US US17/189,881 patent/US11234980B2/en active Active
- 2021-05-31 CO CONC2021/0007186A patent/CO2021007186A2/es unknown
- 2021-06-10 PH PH12021551371A patent/PH12021551371A1/en unknown
- 2021-06-17 IL IL284136A patent/IL284136A/en unknown
- 2021-06-18 CL CL2021001636A patent/CL2021001636A1/es unknown
- 2021-07-20 ZA ZA2021/05111A patent/ZA202105111B/en unknown
- 2021-10-29 US US17/515,132 patent/US11464777B2/en active Active
-
2022
- 2022-09-27 US US17/953,530 patent/US20230020241A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2021001636A1 (es) | 2022-02-18 |
US20230020241A1 (en) | 2023-01-19 |
ZA202105111B (en) | 2023-03-29 |
CO2021007186A2 (es) | 2021-06-10 |
EP3897646A1 (fr) | 2021-10-27 |
US20220096476A1 (en) | 2022-03-31 |
KR20210109558A (ko) | 2021-09-06 |
US11234980B2 (en) | 2022-02-01 |
WO2020128017A1 (fr) | 2020-06-25 |
MX2021007455A (es) | 2021-08-05 |
TW202034923A (zh) | 2020-10-01 |
PH12021551371A1 (en) | 2021-11-29 |
CN113194953A (zh) | 2021-07-30 |
AU2019410727A1 (en) | 2021-08-12 |
MA54522A (fr) | 2022-03-23 |
IL284136A (en) | 2021-08-31 |
EP3897646B1 (fr) | 2024-05-22 |
BR112021011999A2 (pt) | 2021-09-08 |
CA3123990A1 (fr) | 2020-06-25 |
US11464777B2 (en) | 2022-10-11 |
SG11202105098VA (en) | 2021-06-29 |
JP2022512493A (ja) | 2022-02-04 |
JOP20210153A1 (ar) | 2023-01-30 |
US20210196715A1 (en) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI3897646T3 (fi) | Masitentaani keuhkovaltimoverenpainetaudin hoitoon | |
AU2013336491B2 (en) | Pharmaceutical antiretroviral composition | |
FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
NO341573B1 (no) | Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen | |
FI2508188T3 (fi) | Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita | |
TW200726467A (en) | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | |
JP2009518415A5 (fr) | ||
RU2011123876A (ru) | Антисмысловые композиции и способы их получения и применения | |
WO2006089312A3 (fr) | Formulations orales de cci-779 biodisponibles | |
HRP20131233T1 (hr) | Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor | |
EP2316435A1 (fr) | La composition pharmaceutique des inhibiteurs de la PDE-5 et dapoxetine | |
JP2023502530A (ja) | Hiv予防のためのカプシド阻害剤 | |
FI3294283T3 (fi) | Sakubitriili-valsartaani-annostusohjelma sydämen vajaatoiminnan hoitamiseksi | |
WO2008142572A3 (fr) | Formulation de comprimé à libération contrôlée contenant de l'aluminométasilicate de magnésium | |
RU2003100507A (ru) | Фармацевтические композиции | |
US20150104511A1 (en) | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine | |
JP2013508289A5 (fr) | ||
MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
RU2016117186A (ru) | Комбинированная композиция, содержащая тадалафил и амлодипин | |
AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
Rashid | The efficacy and safety of PDE5 inhibitors | |
PE20230859A1 (es) | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina | |
MX2021008208A (es) | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. | |
CA2416771A1 (fr) | Acide 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetique pour le traitement de troubles relies au cox-2 | |
CA2537748A1 (fr) | Utilisation de telmisartan pour la prevention de la cephalee vasculaire |